Top

Published in:

01-06-2015

Association of chromosome 19 to lung cancer genotypes and phenotypes

Authors: Xiangdong Wang, Yong Zhang, Carol L. Nilsson, Frode S. Berven, Per E. Andrén, Elisabet Carlsohn, Peter Horvatovich, Johan Malm, Manuel Fuentes, Ákos Végvári, Charlotte Welinder, Thomas E. Fehniger, Melinda Rezeli, Goutham Edula, Sophia Hober, Toshihide Nishimura, György Marko-Varga

Published in: Cancer and Metastasis Reviews | Issue 2/2015

Abstract

The Chromosome 19 Consortium, a part of the Chromosome-Centric Human Proteome Project (C-HPP, http://www.C-HPP.org), is tasked with the understanding chromosome 19 functions at the gene and protein levels, as well as their roles in lung oncogenesis. Comparative genomic hybridization (CGH) studies revealed chromosome aberration in lung cancer subtypes, including ADC, SCC, LCC, and SCLC. The most common abnormality is 19p loss and 19q gain. Sixty-four aberrant genes identified in previous genomic studies and their encoded protein functions were further validated in the neXtProt database (http://www.nextprot.org/). Among those, the loss of tumor suppressor genes STK11, MUM1, KISS1R (19p13.3), and BRG1 (19p13.13) is associated with lung oncogenesis or remote metastasis. Gene aberrations include translocation t(15, 19) (q13, p13.1) fusion oncogene BRD4-NUT, DNA repair genes (ERCC1, ERCC2, XRCC1), TGFβ1 pathway activation genes (TGFB1, LTBP4), Dyrk1B, and potential oncogenesis protector genes such as NFkB pathway inhibition genes (NFKBIB, PPP1R13L) and EGLN2. In conclusion, neXtProt is an effective resource for the validation of gene aberrations identified in genomic studies. It promises to enhance our understanding of lung cancer oncogenesis.

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. doi:10.3322/caac.21262.

Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62(1), 10–29. doi:10.3322/caac.20138.

Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X. S., et al. (2014). Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. doi:10.1016/S0140-6736(14)62038-9.PubMed

Bronte, G., Rizzo, S., La Paglia, L., Adamo, V., Siragusa, S., Ficorella, C., et al. (2010). Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treatment Reviews, 36(Suppl 3), S21–S29. doi:10.1016/S0305-7372(10)70016-5.PubMedCrossRef

Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561–566. doi:10.1038/nature05945.PubMedCrossRef

Legrain, P., Aebersold, R., Archakov, A., Bairoch, A., Bala, K., Beretta, L., et al. (2011). The human proteome project: current state and future direction. Molecular and Cellular Proteomics, 10(7), M111 009993. doi:10.1074/mcp.M111.009993.PubMedCentralPubMedCrossRef

Hancock, W., Omenn, G., Legrain, P., & Paik, Y. K. (2011). Proteomics, human proteome project, and chromosomes. Journal of Proteome Research, 10(1), 210. doi:10.1021/pr101099h.PubMedCrossRef

Paik, Y. K., Jeong, S. K., Omenn, G. S., Uhlen, M., Hanash, S., Cho, S. Y., et al. (2012). The chromosome-centric human proteome project for cataloging proteins encoded in the genome. Nature Biotechnology, 30(3), 221–223. doi:10.1038/nbt.2152.PubMedCrossRef

Uhlen, M., Oksvold, P., Algenas, C., Hamsten, C., Fagerberg, L., Klevebring, D., et al. (2012). Antibody-based protein profiling of the human chromosome 21. Molecular and Cellular Proteomics, 11(3), M111 013458. doi:10.1074/mcp.M111.013458.PubMedCentralPubMedCrossRef

10.

A gene-centric human proteome project, HUPO–the Human Proteome organization. (2010). Molecular and Cellular Proteomics, 9(2), 427–429. doi:10.1074/mcp.H900001-MCP200.CrossRef

11.

Nilsson, C. L., Berven, F., Selheim, F., Liu, H., Moskal, J. R., Kroes, R. A., et al. (2013). Chromosome 19 annotations with disease speciation: a first report from the Global Research Consortium. Journal of Proteome Research, 12(1), 135–150. doi:10.1021/pr3008607.PubMedCentralPubMedCrossRef

12.

Lichti, C. F., Liu, H., Shavkunov, A. S., Mostovenko, E., Sulman, E. P., Ezhilarasan, R., et al. (2014). Integrated chromosome 19 transcriptomic and proteomic data sets derived from glioma cancer stem-cell lines. Journal of Proteome Research, 13(1), 191–199. doi:10.1021/pr400786s.PubMedCrossRef

13.

Lichti, C. F., Mostovenko, E., Wadsworth, P. A., Lynch, G. C., Pettitt, B. M., Sulman, E. P., et al. (2015). Systematic identification of single amino Acid variants in glioma stem-cell-derived chromosome 19 proteins. Journal of Proteome Research, 14(2), 778–786. doi:10.1021/pr500810g.PubMedCrossRef

14.

Grimwood, J., Gordon, L. A., Olsen, A., Terry, A., Schmutz, J., Lamerdin, J., et al. (2004). The DNA sequence and biology of human chromosome 19. Nature, 428(6982), 529–535. doi:10.1038/nature02399.PubMedCrossRef

15.

Marko-Varga, G., Lindberg, H., Lofdahl, C. G., Jonsson, P., Hansson, L., Dahlback, M., et al. (2005). Discovery of biomarker candidates within disease by protein profiling: principles and concepts. Journal of Proteome Research, 4(4), 1200–1212. doi:10.1021/pr050122w.PubMedCrossRef

16.

Yen, C. C., Liang, S. C., Jong, Y. J., Chen, Y. J., Lin, C. H., Chen, Y. M., et al. (2007). Chromosomal aberrations of malignant pleural effusions of lung adenocarcinoma: different cytogenetic changes are correlated with genders and smoking habits. Lung Cancer, 57(3), 292–301. doi:10.1016/j.lungcan.2007.04.007.PubMedCrossRef

17.

Choi, J. S., Zheng, L. T., Ha, E., Lim, Y. J., Kim, Y. H., Wang, Y. P., et al. (2006). Comparative genomic hybridization array analysis and real-time PCR reveals genomic copy number alteration for lung adenocarcinomas. Lung, 184(6), 355–362. doi:10.1007/s00408-006-0009-0.PubMedCrossRef

18.

Broet, P., Dalmasso, C., Tan, E. H., Alifano, M., Zhang, S., Wu, J., et al. (2011). Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clinical Cancer Research, 17(11), 3542–3550. doi:10.1158/1078-0432.CCR-10-2185.PubMedCrossRef

19.

Wong, M. P., Lam, W. K., Wang, E., Chiu, S. W., Lam, C. L., & Chung, L. P. (2002). Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. Cancer Research, 62(15), 4464–4468.PubMed

20.

Shen, H., Zhu, Y., Wu, Y. J., Qiu, H. R., & Shu, Y. Q. (2008). Genomic alterations in lung adenocarcinomas detected by multicolor fluorescence in situ hybridization and comparative genomic hybridization. Cancer Genetics and Cytogenetics, 181(2), 100–107. doi:10.1016/j.cancergencyto.2007.11.012.PubMedCrossRef

21.

Choi, Y. W., Choi, J. S., Zheng, L. T., Lim, Y. J., Yoon, H. K., Kim, Y. H., et al. (2007). Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung. Lung Cancer, 55(1), 43–51. doi:10.1016/j.lungcan.2006.09.018.PubMedCrossRef

22.

Boelens, M. C., Kok, K., van der Vlies, P., van der Vries, G., Sietsma, H., Timens, W., et al. (2009). Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer, 66(3), 372–378. doi:10.1016/j.lungcan.2009.02.017.PubMedCrossRef

23.

Kayser, K., Kosjerina, Z., Goldmann, T., Kayser, G., Kazmierczak, B., & Vollmer, E. (2005). Lung carcinoma-associated atypical adenomatoid hyperplasia, squamous cell dysplasia, and chromosome alterations in non-neoplastic bronchial mucosa. Lung Cancer, 47(2), 205–214. doi:10.1016/j.lungcan.2004.07.042.PubMedCrossRef

24.

Umemura, S., Mimaki, S., Makinoshima, H., Tada, S., Ishii, G., Ohmatsu, H., et al. (2014). Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. Journal of Thoracic Oncology, 9(9), 1324–1331. doi:10.1097/JTO.0000000000000250.PubMedCentralPubMedCrossRef

25.

Vogel, U., Laros, I., Jacobsen, N. R., Thomsen, B. L., Bak, H., Olsen, A., et al. (2004). Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer. Mutation Research, 546(1-2), 65–74.PubMedCrossRef

26.

Yin, J., Vogel, U., Ma, Y., Qi, R., & Wang, H. (2008). Haplotypes of nine single nucleotide polymorphisms on chromosome 19q13.2-3 associated with susceptibility of lung cancer in a Chinese population. Mutation Research, 641(1-2), 12–18. doi:10.1016/j.mrfmmm.2008.02.004.PubMedCrossRef

27.

Bloom, A. J., Baker, T. B., Chen, L. S., Breslau, N., Hatsukami, D., Bierut, L. J., et al. (2014). Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. Human Molecular Genetics, 23(2), 555–561. doi:10.1093/hmg/ddt432.PubMedCentralPubMedCrossRef

28.

Ryan, D. M., Vincent, T. L., Salit, J., Walters, M. S., Agosto-Perez, F., Shaykhiev, R., et al. (2014). Smoking dysregulates the human airway basal cell transcriptome at COPD risk locus 19q13.2. PLoS One, 9(2), e88051. doi:10.1371/journal.pone.0088051.PubMedCentralPubMedCrossRef

29.

Li, Y., Huang, J., & Amos, C. I. (2012). Genetic association analysis of complex diseases incorporating intermediate phenotype information. PLoS One, 7(10), e46612. doi:10.1371/journal.pone.0046612.PubMedCentralPubMedCrossRef

30.

Yin, J., Vogel, U., Wang, H., Ma, Y., Wang, C., Liang, D., et al. (2013). HapMap-based study identifies risk sub-region on chromosome 19q13.3 in relation to lung cancer among Chinese. Cancer Epidemiology, 37(6), 923–929. doi:10.1016/j.canep.2013.09.016.PubMedCrossRef

31.

Timofeeva, M. N., McKay, J. D., Smith, G. D., Johansson, M., Byrnes, G. B., Chabrier, A., et al. (2011). Genetic polymorphisms in 15q25 and 19q13 loci, cotinine levels, and risk of lung cancer in EPIC. Cancer Epidemiology, Biomarkers and Prevention, 20(10), 2250–2261. doi:10.1158/1055-9965.EPI-11-0496.PubMedCrossRef

32.

Sanchez-Cespedes, M., Ahrendt, S. A., Piantadosi, S., Rosell, R., Monzo, M., Wu, L., et al. (2001). Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Research, 61(4), 1309–1313.PubMed

33.

Yin, J., Guo, L., Wang, C., Wang, H., Ma, Y., Liu, J., et al. (2013). Effects of PPP1R13L and CD3EAP variants on lung cancer susceptibility among nonsmoking Chinese women. Gene, 524(2), 228–231. doi:10.1016/j.gene.2013.04.017.PubMedCrossRef

34.

Ruosaari, S. T., Nymark, P. E., Aavikko, M. M., Kettunen, E., Knuutila, S., Hollmen, J., et al. (2008). Aberrations of chromosome 19 in asbestos-associated lung cancer and in asbestos-induced micronuclei of bronchial epithelial cells in vitro. Carcinogenesis, 29(5), 913–917. doi:10.1093/carcin/bgn068.PubMedCrossRef

35.

Wikman, H., Ruosaari, S., Nymark, P., Sarhadi, V. K., Saharinen, J., Vanhala, E., et al. (2007). Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer. Oncogene, 26(32), 4730–4737. doi:10.1038/sj.onc.1210270.PubMedCrossRef

36.

Nymark, P., Aavikko, M., Makila, J., Ruosaari, S., Hienonen-Kempas, T., Wikman, H., et al. (2013). Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients. Molecular Oncology, 7(1), 29–40. doi:10.1016/j.molonc.2012.07.006.PubMedCrossRef

37.

Hu, Y., Gao, Y. N., Feng, F. Y., Lin, D. M., & Jiao, S. C. (2010). Analysis of first-line chemoresistance and prediction of chemo-response in non-small cell lung cancer by comparative genomic hybridization. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 32(4), 389–393. doi:10.3881/j.issn.1000-503X.2010.04.006.PubMed

38.

Felip, E., & Rosell, R. (2007). Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Review of Molecular Diagnostics, 7(3), 261–268. doi:10.1586/14737159.7.3.261.PubMedCrossRef

39.

Carpagnano, G. E., Palladino, G. P., Gramiccioni, C., Foschino Barbaro, M. P., & Martinelli, D. (2010). Exhaled ERCC-1 and ERCC-2 microsatellite alterations in NSCLC patients. Lung Cancer, 68(2), 305–307. doi:10.1016/j.lungcan.2010.01.020.PubMedCrossRef

40.

Rydzanicz, M., Giefing, M., Ziolkowski, A., Kasprzyk, M., Gabriel, A., Dyszkiewicz, W., et al. (2008). Nonrandom DNA copy number changes related to lymph node metastases in squamous cell carcinoma of the lung. Neoplasma, 55(6), 493–500.PubMed

41.

Goode, R. J., Yu, S., Kannan, A., Christiansen, J. H., Beitz, A., Hancock, W. S., et al. (2013). The proteome browser web portal. Journal of Proteome Research, 12(1), 172–178. doi:10.1021/pr3010056.PubMedCrossRef

42.

Gazdar, A. F., Bader, S., Hung, J., Kishimoto, Y., Sekido, Y., Sugio, K., et al. (1994). Molecular genetic changes found in human lung cancer and its precursor lesions. Cold Spring Harbor Symposia on Quantitative Biology, 59, 565–572.PubMedCrossRef

43.

von Herbay, A., Arens, N., Friedl, W., Vogt-Moykopf, I., Kayser, K., Muller, K. M., et al. (2005). Bronchioloalveolar carcinoma: a new cancer in Peutz-Jeghers syndrome. Lung Cancer, 47(2), 283–288. doi:10.1016/j.lungcan.2004.06.015.CrossRef

44.

Gill, R. K., Yang, S. H., Meerzaman, D., Mechanic, L. E., Bowman, E. D., Jeon, H. S., et al. (2011). Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene, 30(35), 3784–3791. doi:10.1038/onc.2011.98.PubMedCentralPubMedCrossRef

45.

Shaw, R. J. (2009). LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiologica (Oxford, England), 196(1), 65–80. doi:10.1111/j.1748-1716.2009.01972.x.CrossRef

46.

Sanchez-Cespedes, M. (2011). The role of LKB1 in lung cancer. Familial Cancer, 10(3), 447–453. doi:10.1007/s10689-011-9443-0.PubMedCrossRef

47.

Shaw, R. J. (2009). Tumor suppression by LKB1: SIK-ness prevents metastasis. Science Signaling, 2(86), pe55. doi:10.1126/scisignal.286pe55.PubMedCrossRef

48.

Rodriguez-Nieto, S., & Sanchez-Cespedes, M. (2009). BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer. Carcinogenesis, 30(4), 547–554. doi:10.1093/carcin/bgp035.PubMedCrossRef

49.

Orvis, T., Hepperla, A., Walter, V., Song, S., Simon, J., Parker, J., et al. (2014). BRG1/SMARCA4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization. Cancer Research, 74(22), 6486–6498. doi:10.1158/0008-5472.CAN-14-0061.PubMedCrossRef

50.

Huen, M. S., Huang, J., Leung, J. W., Sy, S. M., Leung, K. M., Ching, Y. P., et al. (2010). Regulation of chromatin architecture by the PWWP domain-containing DNA damage-responsive factor EXPAND1/MUM1. Molecular Cell, 37(6), 854–864. doi:10.1016/j.molcel.2009.12.040.PubMedCentralPubMedCrossRef

51.

Sun, Y. B., & Xu, S. (2013). Expression of KISS1 and KISS1R (GPR54) may be used as favorable prognostic markers for patients with non-small cell lung cancer. International Journal of Oncology, 43(2), 521–530. doi:10.3892/ijo.2013.1967.PubMed

52.

Vargas, S. O., French, C. A., Faul, P. N., Fletcher, J. A., Davis, I. J., Dal Cin, P., et al. (2001). Upper respiratory tract carcinoma with chromosomal translocation 15;19: evidence for a distinct disease entity of young patients with a rapidly fatal course. Cancer, 92(5), 1195–1203.PubMedCrossRef

53.

French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Perez-Atayde, A. R., & Fletcher, J. A. (2003). BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Research, 63(2), 304–307.PubMed

54.

Thompson-Wicking, K., Francis, R. W., Stirnweiss, A., Ferrari, E., Welch, M. D., Baker, E., et al. (2013). Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. Oncogene, 32(39), 4664–4674. doi:10.1038/onc.2012.487.PubMedCrossRef

55.

Haruki, N., Kawaguchi, K. S., Eichenberger, S., Massion, P. P., Gonzalez, A., Gazdar, A. F., et al. (2005). Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro. Journal of Medical Genetics, 42(7), 558–564. doi:10.1136/jmg.2004.029686.PubMedCentralPubMedCrossRef

56.

Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999). Notch signaling: cell fate control and signal integration in development. Science, 284(5415), 770–776.PubMedCrossRef

57.

Dang, T. P., Gazdar, A. F., Virmani, A. K., Sepetavec, T., Hande, K. R., Minna, J. D., et al. (2000). Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. Journal of the National Cancer Institute, 92(16), 1355–1357.PubMedCrossRef

58.

Zou, Z., Huang, B., Wu, X., Zhang, H., Qi, J., Bradner, J., et al. (2014). Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA. Oncogene, 33(18), 2395–2404. doi:10.1038/onc.2013.179.PubMedCentralPubMedCrossRef

59.

Wu, S. Y., Lee, A. Y., Lai, H. T., Zhang, H., & Chiang, C. M. (2013). Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Molecular Cell, 49(5), 843–857. doi:10.1016/j.molcel.2012.12.006.PubMedCentralPubMedCrossRef

60.

Simon, G. R., Sharma, S., Cantor, A., Smith, P., & Bepler, G. (2005). ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 127(3), 978–983. doi:10.1378/chest.127.3.978.PubMedCrossRef

61.

Vanhecke, E., Valent, A., Tang, X., Vielh, P., Friboulet, L., Tang, T., et al. (2013). 19q13-ERCC1 gene copy number increase in non-small-cell lung cancer. Clinical Lung Cancer, 14(5), 549–557. doi:10.1016/j.cllc.2013.01.006.PubMedCrossRef

62.

Dobashi, Y., Kimura, M., Matsubara, H., Endo, S., Inazawa, J., & Ooi, A. (2012). Molecular alterations in AKT and its protein activation in human lung carcinomas. Human Pathology, 43(12), 2229–2240. doi:10.1016/j.humpath.2012.03.015.PubMedCrossRef

63.

Bokobza, S. M., Jiang, Y., Weber, A. M., Devery, A. M., & Ryan, A. J. (2014). Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells. Oncotarget, 5(13), 4765–4778.PubMedCentralPubMed

64.

Koli, K., Wempe, F., Sterner-Kock, A., Kantola, A., Komor, M., Hofmann, W. K., et al. (2004). Disruption of LTBP-4 function reduces TGF-beta activation and enhances BMP-4 signaling in the lung. Journal of Cell Biology, 167(1), 123–133. doi:10.1083/jcb.200403067.PubMedCentralPubMedCrossRef

65.

Li, H., Da, L. J., Fan, W. D., Long, X. H., & Zhang, X. Q. (2015). Transcription factor glioma-associated oncogene homolog 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition of non-small cell lung cancer cells. Molecular Medicine Reports, 11(5), 3259–3268. doi:10.3892/mmr.2015.3150.PubMedCentralPubMed

66.

Kong, F. F., Zhu, Y. L., Yuan, H. H., Wang, J. Y., Zhao, M., Gong, X. D., et al. (2014). FOXM1 regulated by ERK pathway mediates TGF-beta1-Induced EMT in NSCLC. Oncology Research, 22(1), 29–37. doi:10.3727/096504014X14078436004987.PubMedCrossRef

67.

Yang, J. P., Hori, M., Sanda, T., & Okamoto, T. (1999). Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. Journal of Biological Chemistry, 274(22), 15662–15670.PubMedCrossRef

68.

Slee, E. A., Gillotin, S., Bergamaschi, D., Royer, C., Llanos, S., Ali, S., et al. (2004). The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene, 23(56), 9007–9016. doi:10.1038/sj.onc.1208088.PubMedCrossRef

69.

Mantovani, F., Tocco, F., Girardini, J., Smith, P., Gasco, M., Lu, X., et al. (2007). The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nature Structural and Molecular Biology, 14(10), 912–920. doi:10.1038/nsmb1306.PubMedCrossRef

70.

Gao, J., Zheng, Z., Rawal, B., Schell, M. J., Bepler, G., & Haura, E. B. (2009). Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biology and Therapy, 8(17), 1671–1679.PubMedCentralPubMedCrossRef

71.

Gao, J., Zhao, Y., Lv, Y., Chen, Y., Wei, B., Tian, J., et al. (2013). Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells. Cancer Cell International, 13(1), 2. doi:10.1186/1475-2867-13-2.PubMedCentralPubMedCrossRef

72.

Che, J., Jiang, D., Zheng, Y., Zhu, B., Zhang, P., Lu, D., et al. (2014). Polymorphism in PHD1 gene and risk of non-small cell lung cancer in a Chinese population. Tumour Biology, 35(9), 8921–8925. doi:10.1007/s13277-014-2112-9.PubMedCrossRef

73.

Xie, X., Xiao, H., Ding, F., Zhong, H., Zhu, J., Ma, N., et al. (2014). Over-expression of prolyl hydroxylase-1 blocks NF-kappaB-mediated cyclin D1 expression and proliferation in lung carcinoma cells. Cancer Genet, 207(5), 188–194. doi:10.1016/j.cancergen.2014.04.008.PubMedCrossRef

Title: Association of chromosome 19 to lung cancer genotypes and phenotypes
Authors: Xiangdong Wang
Yong Zhang
Carol L. Nilsson
Frode S. Berven
Per E. Andrén
Elisabet Carlsohn
Peter Horvatovich
Johan Malm
Manuel Fuentes
Ákos Végvári
Charlotte Welinder
Thomas E. Fehniger
Melinda Rezeli
Goutham Edula
Sophia Hober
Toshihide Nishimura
György Marko-Varga
Publication date: 01-06-2015
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-015-9556-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Application of clinical bioinformatics in lung cancer-specific biomarkers

Regulatory T cells and potential inmmunotherapeutic targets in lung cancer

Roles of CEACAM1 in cell communication and signaling of lung cancer and other diseases

Targeting roles of inflammatory microenvironment in lung cancer and metastasis

Erratum to: Association of chromosome 19 to lung cancer genotypes and phenotypes

Global analyses of subtype- or stage-specific genes on chromosome 7 in patients with lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer